BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang Y, Zhou Q, Tang R, Huang Y, He T. FoxM1 inhibition ameliorates renal interstitial fibrosis by decreasing extracellular matrix and epithelial-mesenchymal transition. J Pharmacol Sci 2020;143:281-9. [PMID: 32513569 DOI: 10.1016/j.jphs.2020.05.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Bailly C. The bacterial thiopeptide thiostrepton. An update of its mode of action, pharmacological properties and applications. Eur J Pharmacol 2022;914:174661. [PMID: 34863996 DOI: 10.1016/j.ejphar.2021.174661] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Luo M, Liu M, Liu W, Cui X, Zhai S, Gu H, Wang H, Wu K, Zhang W, Li K, Xia Y. Inhibition of fibroblast growth factor-inducible 14 attenuates experimental tubulointerstitial fibrosis and profibrotic factor expression of proximal tubular epithelial cells. Inflamm Res 2021;70:553-68. [PMID: 33755760 DOI: 10.1007/s00011-021-01455-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Yang N, Cao DF, Yin XX, Zhou HH, Mao XY. Lysyl oxidases: Emerging biomarkers and therapeutic targets for various diseases. Biomed Pharmacother 2020;131:110791. [PMID: 33152948 DOI: 10.1016/j.biopha.2020.110791] [Cited by in F6Publishing: 4] [Reference Citation Analysis]